Table 3.
Association of Genotype with Overall Survival
| Genotype | Training |
Validation |
Combined dataset |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients/No. of Deaths | MST | HR† (95%CI) | P† | No. of Patients/No. of Deaths | MST | HR† (95%CI) | P† | MST | HR† (95% CI) | P† | |
| IGF1 *8470T>C | |||||||||||
| CC | 150/94 | 28.7 | 1.0 | 161/145 | 11.4 | 1.0 | 16.5 | 1.0 | |||
| CT | 142/110 | 29.8 | 1.38 (1.04–1.83) | .02 | 169/149 | 12.5 | 0.97 (0.77–1.22) | .80 | 17.7 | 1.08 (0.90–1.29) | .39 |
| TT | 41/33 | 25.7 | 2.01 (1.33–3.03) | <.001 | 38/33 | 13.5 | 0.89 (0.60–1.31) | .55 | 18.0 | 1.22 (0.92–1.61) | .16 |
| IGF1R IVS2+46329T>C | |||||||||||
| CC | 140/89 | 33.3 | 1.0 | 120/109 | 14.5 | 1.0 | 20.5 | 1.0 | |||
| TC | 144/112 | 24.3 | 1.49 (1.12–1.99) | .006 | 178/161 | 11.4 | 1.23 (0.96–1.58) | .11 | 14.4 | 1.34 (1.11–1.62) | .002 |
| TT | 49/36 | 31.0 | 1.06 (0.71–1.58) | .76 | 72/58 | 14.5 | 0.94 (0.68–1.31) | .73 | 18.7 | 1.06 (0.83–1.37) | .62 |
| CC/TT vs. TC | 1.47 (1.13–1.91) | .004 | 1.26 (1.01–1.57) | .04 | 1.32 (1.11–1.56) | .01 | |||||
| IGF1R IVS20-3431A>G | |||||||||||
| AA | 232/170 | 26.4 | 1.0 | 240/211 | 13.2 | 1.0 | 17.6 | 1.0 | |||
| GA | 89/59 | 33.6 | 0.76 (0.56–1.03) | .07 | 122/109 | 10.4 | 1.36 (1.07–1.72) | .01 | 15.3 | 1.12 (0.94–1.35) | .21 |
| GG | 12/8 | 16.2 | 1.11 (0.54–2.29) | .78 | 10/10 | 4.9 | 1.65 (0.85–3.19) | .14 | 12.0 | 1.30 (0.80–2.10) | .29 |
| AA vs. GG/GA | 0.78 (0.58–1.04) | .09 | 1.40 (1.11–1.77) | .004 | 1.14 (0.95–1.36) | .15 | |||||
| IGF1R T766T | |||||||||||
| CC | 301/211 | 30.6 | 1.0 | 327/287 | 12.6 | 1.0 | 18.2 | 1.0 | |||
| CT | 31/25 | 15.5 | 1.59 (1.04–2.45) | .03 | 43/41 | 8.0 | 1.70 (1.20–2.39) | .002 | 10.3 | 1.61 (1.22–2.12) | <.001 |
| TT | 1/1 | 9.2 | 2.60 (0.32–21.1) | .37 | 3/3 | 7.3 | 3.50 (1.02–12.02) | .046 | 7.3 | 2.50 (0.89–7.02) | .08 |
| CC vs. CT/TT | 1.61 (1.06–2.46) | .02 | 1.77 (1.27–2.47) | <.001 | 1.66 (1.28–2.16) | <.001 | |||||
| IGF2R L252V | |||||||||||
| CC | 256/175 | 30.4 | 1.0 | 288/261 | 12.0 | 1.0 | 17.5 | 1.0 | |||
| CG | 72/57 | 26.2 | 1.20 (0.88–1.64) | .24 | 75/61 | 13.6 | 0.86 (0.65–1.15) | .32 | 16.4 | 1.01 (0.82–1.24) | .95 |
| GG | 5/5 | 11.0 | 2.92 (1.09–7.77) | .03 | 9/8 | 11.1 | 1.67 (0.82–3.42) | .16 | 11.0 | 2.36 (1.31–4.23) | .004 |
| CC vs. GG/CG | 2.81 (1.06–7.47) | .038 | 1.73 (0.85–3.52) | .13 | |||||||
| IGF2R S350S | |||||||||||
| AA | 156/97 | 36.4 | 1.0 | 156/143 | 12.4 | 1.0 | 18.7 | 1.0 | |||
| AG | 139/107 | 21.7 | 1.28 (0.96–1.70) | .09 | 158/139 | 12.0 | 1.00 (0.78–1.26) | .97 | 16.5 | 1.11 (0.92–1.33) | .26 |
| GG | 38/33 | 22.9 | 1.72 (1.13–2.61) | .01 | 59/49 | 12.1 | 1.02 (0.74–1.42) | .89 | 15.1 | 1.25 (0.97–1.62) | .09 |
| IGFBP3 A32G | |||||||||||
| GG | 137/108 | 22.9 | 1.0 | 132/114 | 11.1 | 1.0 | 16.4 | 1.0 | |||
| GC | 145/99 | 29.8 | 0.71 (0.54–0.93) | .01 | 176/157 | 13.9 | 0.89 (0.69–1.13) | .33 | 17.9 | 0.81 (0.67–0.97) | .02 |
| CC | 49/30 | 34.8 | 0.58 (0.38–0.87) | .009 | 65/60 | 11.8 | 1.08 (0.78–1.48) | .65 | 15.3 | 0.88 (0.69–1.13) | .33 |
| GG vs. CC/GC | 0.67 (0.52–0.87) | .003 | 0.93 (0.74–1.18) | .55 | 0.83 (0.70–0.98) | .029 | |||||
| IGFBP3 -202A>C | |||||||||||
| CC | 72/57 | 24.5 | 85/73 | 10.3 | 1.0 | 14.7 | |||||
| AC | 173/119 | 30.1 | 0.72 (0.52–0.99) | .046 | 195/175 | 13.4 | 0.65 (0.49–0.87) | .003 | 17.8 | 0.68 (0.55–0.84) | <.001 |
| AA | 88/61 | 28.5 | 0.69 (0.48–0.99) | .049 | 93/83 | 12.5 | 0.70 (0.50–0.98) | .039 | 17.6 | 0.71 (0.55–0.91) | .006 |
| CC vs. AA/AC | 0.71 (0.52–0.96) | .02 | 0.67 (0.51–0.87) | .003 | 0.69 (0.57–0.84) | <.001 | |||||
| IRS1 IVS1+4315C>G | |||||||||||
| CC | 284/199 | 30.4 | 1.0 | 327/289 | 12.0 | 1.0 | 17.3 | 1.0 | |||
| CG | 46/35 | 18.2 | 1.39 (0.96–2.02) | .08 | 42/38 | 12.3 | 1.15 (0.8–1.65) | .44 | 17.2 | 1.22 (0.94–1.57) | .13 |
| GG | 3/3 | 9.2 | 4.26 (1.25–14.5) | .02 | 2/2 | 3.2 | 22.8 (5.21–99.4) | <.001 | 3.5 | 5.63 (2.25–14.0) | <.001 |
| CC vs. CG/GG | 1.47 (1.02–2.11) | .03 | 1.23 (0.87–1.74) | .24 | 1.29 (1.01–1.65) | .04 | |||||
| IRS1 G972R | |||||||||||
| GG | 292/204 | 30.4 | 1.0 | 314/277 | 12.7 | 1.0 | 18.2 | 1.0 | |||
| GA | 38/30 | 12.9 | 1.65 (1.11–2.46) | .01 | 54/51 | 8.5 | 1.42 (1.05–1.93) | .02 | 10.1 | 1.50 (1.18–1.91) | .001 |
| AA | 3/3 | 6.2 | 3.25 (1.01–10.4) | .047 | 5/3 | 3.8 | 1.43 (0.44–4.58) | .55 | 6.2 | 2.26 (1.00–5.11) | .05 |
| GG vs. GA/AA | 1.74 (1.19–2.54) | .005 | 1.49 (1.10–2.01) | .009 | 1.53 (1.21–1.94) | <.001 | |||||
| IRS2 IVS1+5687T>C | |||||||||||
| TT | 205/140 | 31.2 | 1.0 | 132/112 | 13.6 | 1.0 | 20.7 | 1.0 | |||
| CT | 101/80 | 25.1 | 1.42 (1.06–1.89) | .01 | 179/164 | 12.0 | 1.24 (0.97–1.59) | .08 | 15.1 | 1.24 (1.03–1.49) | .02 |
| CC | 20/14 | 28.5 | 1.56 (0.89–2.73) | .12 | 43/39 | 10.1 | 1.45 (0.99–2.11) | .05 | 12.5 | 1.46 (1.07–1.98) | .01 |
| TT vs. CT/CC | 1.44 (1.09–1.89) | .009 | 132/112 | 11.8 | 1.28 (1.01–1.62) | .04 | 1.27 (1.07–1.52) | .007 | |||
| IRS4 A20A | |||||||||||
| GG | 244/167 | 30.1 | 275/238 | 12.2 | 17.5 | ||||||
| GA | 43/35 | 28.1 | 1.20 (0.80–1.80) | .37 | 54/50 | 11.8 | 1.31 (0.81–1.59) | .48 | 14.7 | 1.13 (0.87–1.46) | .35 |
| AA | 37/28 | 25.0 | 1.55 (1.01–2.39) | .048 | 41/40 | 12.8 | 1.10 (0.77–1.56) | .61 | 18.1 | 1.25 (0.96–1.64) | .10 |
| GG vs. GA/AA | 1.52 (1.00–2.34) | .05 | 1.11 (0.86–1.44) | .41 | 1.19 (0.97–1.44) | .09 | |||||
MST, median survival time (months); CI, confidence interval; HR: hazard ratio; CA19-9, carbohydrate antigen 19-9.
†
HR was estimated from multivariate Cox regression models including sex, race, clinical stage, tumor resection, CA 19-9, biochemical index and performance status